Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (not Alteryx Therapeutics Ltd) covers the quarter ended September 30, 2017. The registrant is a foreign private issuer based in Australia, reporting under Listing Rule 4.7B. The filing primarily consists of a consolidated statement of cash flows and estimated future outflows.
Key Financial Metrics
| Metric | Value (AUD '000) |
|---|---|
| Net Cash Used in Operating Activities | (1,957) |
| Net Cash from Investing Activities | 0 |
| Net Cash from Financing Activities | 0 |
| Cash and Cash Equivalents (End of Quarter) | 19,348 |
| Cash and Cash Equivalents (Beginning of Quarter) | 21,884 |
| Effect of Exchange Rates | (579) |
| Payments to Directors | 207 |
| Estimated Cash Outflows (Next Quarter) | 2,813 |
Revenue and Profit: The filing text does not provide a clear value for revenue or net profit. The cash flow statement shows zero receipts from customers and zero dividends received.
Debt and Liquidity: The company reported no loan facilities or credit standby arrangements drawn at quarter end. Liquidity is supported by bank balances of $9,348,000 and call deposits of $10,000,000.
Material Changes
The filing does not explicitly detail material changes compared to the prior comparable period. However, cash and cash equivalents decreased from $21,884,000 to $19,348,000 during the quarter, driven by a net operating cash outflow of $1,957,000 and a negative exchange rate impact of $579,000.
Outlook, Risks, and Management Commentary
Estimated Future Outflows: Management estimates total cash outflows for the next quarter at $2,813,000. The primary components are:
- Research and development: $1,434,000
- Administration and corporate costs: $684,000
- Staff costs: $670,000
- Advertising and marketing: $25,000
Risks and Contingencies: The filing does not explicitly list specific risks or contingencies beyond the standard disclosure of cash burn and the absence of financing facilities. The company relies on existing cash reserves to fund operations.
Investor Verification Checklist
- Verify the discrepancy between the request metadata ("Alteryx Therapeutics Ltd") and the filing registrant ("Prana Biotechnology Limited").
- Confirm the absence of revenue generation in the current quarter as indicated by zero customer receipts.
- Assess the runway provided by the $19.3 million cash balance against the estimated $2.8 million quarterly burn rate.
- Review the impact of foreign exchange rates on cash holdings, which reduced liquidity by $579,000 in this quarter.
- Check for any subsequent financing activities not captured in this quarterly snapshot.